Global Information
회사소개 | 문의 | 비교리스트

하이드록시클로로퀸 : 세계 시장 전망(2018-2027년)

Hydroxychloroquine - Global Market Outlook (2018-2027)

리서치사 Stratistics Market Research Consulting
발행일 2020년 05월 상품 코드 939095
페이지 정보 영문 140 Pages
가격
US $ 4,150 ₩ 4,728,000 PDF by E-mail (Single User License)
US $ 5,250 ₩ 5,981,000 PDF by E-mail (2-5 User License)
US $ 6,350 ₩ 7,235,000 PDF by E-mail (Site License)
US $ 7,500 ₩ 8,545,000 PDF by E-mail (Global Site License)


하이드록시클로로퀸 : 세계 시장 전망(2018-2027년) Hydroxychloroquine - Global Market Outlook (2018-2027)
발행일 : 2020년 05월 페이지 정보 : 영문 140 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 하이드록시클로로퀸 시장은 예측기간 동안 10.4%의 연평균 복합 성장률(CAGR)로 성장을 지속하여 2018년 4,130만 달러에서 2027년까지 1억 62만 달러 규모에 달할 것으로 예측됩니다. 노인 인구 증가, 제3세계 국가에서의 말라리아용 약제에 대한 높은 수요 등의 요인이 시장 성장을 촉진하고 있습니다. 그러나 한편, 제품 리콜 및 생산 판매 중지 등의 요인이 시장 성장을 방해하고 있습니다.

세계의 하이드록시클로로퀸(Hydroxychloroquine) 시장을 조사했으며, 시장 및 제품 개요, 각종 시장 성장 영향요인 및 시장 기회 분석, 유형·투약 경로·그레이드·성분·용도·지역/주요 국가 등 각종 구분별 동향, 시장 규모 추이 및 예측, 경쟁 환경, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

제1장 개요

제2장 서문

제3장 시장 동향 분석

  • 서론
  • 성장 촉진요인
  • 성장 억제요인
  • 시장 기회
  • 위협
  • 용도 분석
  • 신흥 시장
  • 코로나19(Covid-19)의 영향

제4장 Porter's Five Forces 분석

제5장 세계의 하이드록시클로로퀸 시장 : 유형별

  • 서론
  • 타블렛
  • 주사제

제6장 세계의 하이드록시클로로퀸 시장 : 투여 경로별

  • 서론
  • 경구
  • 정맥주사

제7장 세계의 하이드록시클로로퀸 시장 : 그레이드별

  • 서론
  • United States Pharmacopeial Convention(USP) Standards Grade
  • Pharmaceutical Standards Grade
  • European Pharmacopoeia(EP) Standards Grade

제8장 세계의 하이드록시클로로퀸 시장 : 성분별

  • 서론
  • 100 mg
  • 200 mg
  • 250 mg
  • 400 mg
  • 500 mg
  • 800 mg

제9장 세계의 하이드록시클로로퀸 시장 : 유통경로별

  • 서론
  • 원내 약국
  • 온라인 약국
  • 전문 약국
  • 소매 약국
  • 홈케어

제10장 세계의 하이드록시클로로퀸 시장 : 용도별

  • 서론
  • 말라리아
  • 류마티스 관절염
  • 루푸스
    • 전신성 홍반 루푸스
    • 만성 원반모양 홍반 루푸스
  • 피부병변
  • 코로나19(COVID-19)

제11장 세계의 하이드록시클로로퀸 시장 : 지역별

  • 서론
  • 북미
  • 유럽
  • 아시아태평양
  • 남미
  • 중동 및 아프리카

제12장 주요 발전

  • 계약, 제휴, 협업, 합작투자(JV)
  • 인수합병(M&A)
  • 신제품 출시
  • 확장
  • 기타 주요 전략

제13장 기업 개요

  • Hikma Pharmaceuticals PLC
  • Cadila Healthcare Ltd
  • Ipca Laboratories Ltd
  • Novartis AG
  • Mylan NV
  • Sanofi SA
  • Taj Pharmaceuticals Ltd
  • Shanghai Pharmaceuticals Holding Co., Ltd
  • Torrent Pharmaceuticals Ltd
  • Teva Pharmaceutical Industries Ltd
  • Dr. Reddy 's Laboratories Ltd
  • Sun Pharmaceutical Industries Ltd
  • Zydus Cadila
LSH 20.06.12

List of Tables

  • Table 1 Global Hydroxychloroquine Market Outlook, By Region (2017-2027) ($MN)
  • Table 2 Global Hydroxychloroquine Market Outlook, By Type (2017-2027) ($MN)
  • Table 3 Global Hydroxychloroquine Market Outlook, By Tablets (2017-2027) ($MN)
  • Table 4 Global Hydroxychloroquine Market Outlook, By Injection (2017-2027) ($MN)
  • Table 5 Global Hydroxychloroquine Market Outlook, By Route of Administration (2017-2027) ($MN)
  • Table 6 Global Hydroxychloroquine Market Outlook, By Oral (2017-2027) ($MN)
  • Table 7 Global Hydroxychloroquine Market Outlook, By Intravenous (2017-2027) ($MN)
  • Table 8 Global Hydroxychloroquine Market Outlook, By Grade (2017-2027) ($MN)
  • Table 9 Global Hydroxychloroquine Market Outlook, By United States Pharmacopeial Convention (USP) Standards Grade (2017-2027) ($MN)
  • Table 10 Global Hydroxychloroquine Market Outlook, By Pharmaceutical Standards Grade (2017-2027) ($MN)
  • Table 11 Global Hydroxychloroquine Market Outlook, By European Pharmacopoeia (EP) Standards Grade (2017-2027) ($MN)
  • Table 12 Global Hydroxychloroquine Market Outlook, By Strength (2017-2027) ($MN)
  • Table 13 Global Hydroxychloroquine Market Outlook, By 100 mg (2017-2027) ($MN)
  • Table 14 Global Hydroxychloroquine Market Outlook, By 200 mg (2017-2027) ($MN)
  • Table 15 Global Hydroxychloroquine Market Outlook, By 250 mg (2017-2027) ($MN)
  • Table 16 Global Hydroxychloroquine Market Outlook, By 400 mg (2017-2027) ($MN)
  • Table 17 Global Hydroxychloroquine Market Outlook, By 500 mg (2017-2027) ($MN)
  • Table 18 Global Hydroxychloroquine Market Outlook, By 800 mg (2017-2027) ($MN)
  • Table 19 Global Hydroxychloroquine Market Outlook, By Distribution Channel (2017-2027) ($MN)
  • Table 20 Global Hydroxychloroquine Market Outlook, By Hospital Pharmacy (2017-2027) ($MN)
  • Table 21 Global Hydroxychloroquine Market Outlook, By Online Pharmacy (2017-2027) ($MN)
  • Table 22 Global Hydroxychloroquine Market Outlook, By Speciality Drug Stores (2017-2027) ($MN)
  • Table 23 Global Hydroxychloroquine Market Outlook, By Retail Pharmacy (2017-2027) ($MN)
  • Table 24 Global Hydroxychloroquine Market Outlook, By Homeocare (2017-2027) ($MN)
  • Table 25 Global Hydroxychloroquine Market Outlook, By Application (2017-2027) ($MN)
  • Table 26 Global Hydroxychloroquine Market Outlook, By Malaria (2017-2027) ($MN)
  • Table 27 Global Hydroxychloroquine Market Outlook, By Rheumatoid arthritis (2017-2027) ($MN)
  • Table 28 Global Hydroxychloroquine Market Outlook, By Lupus Erythematosus (2017-2027) ($MN)
  • Table 29 Global Hydroxychloroquine Market Outlook, By Systemic Lupus Erythematosus (2017-2027) ($MN)
  • Table 30 Global Hydroxychloroquine Market Outlook, By Chronic Discoid Lupus Erythematosus (2017-2027) ($MN)
  • Table 31 Global Hydroxychloroquine Market Outlook, By Skin Lesions (2017-2027) ($MN)
  • Table 32 Global Hydroxychloroquine Market Outlook, By COVID-19 (2017-2027) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

According to Stratistics MRC, the Global Hydroxychloroquine Market is accounted for $41.30 million in 2018 and is expected to reach $100.62 million by 2027 growing at a CAGR of 10.4% during the forecast period. The rising geriatric population, and the high demand for the drug from third world nations for dealing with malarial are the major factors propelling the market growth. However, factors such as product recalls and discontinuation of drugs are hampering the market growth.

Hydroxychloroquine is a medication and analogue of chloroquine. It has antirheumatic as well as antimalarial properties. It has been used widely for the treatment of infectious as well as rheumatoid arthritis. It has been recognized that clinical use of hydroxychloroquine has significantly improve the treatment rate of patient suffering from the COVID-19. The growth of hydroxychloroquine enhanced by the growing cases of infectious diseases that majorly includes coronavirus and malaria and increase research and development activities. In addition, advances in the treatment options and presence of well-established healthcare facilities are some of the impacting factors for the demand of hydroxychloroquine drugs.

Based on the application, the COVID-19 segment is going to have a lucrative growth during the forecast period as this is a new condition and a large number of trials are conducted on the effectiveness of the medicine in treating the condition, it would contribute to the growth rate witnessed by this segment. The fact that a large number of patients with COVID-19 are admitted to hospitals for treatment results in high preference and dependence on this medicine, contributing to the market share held by this segment.

By geography, Asia Pacific is going to have a lucrative growth during the forecast period attributed to India being the leading producer of the drug and China being the largest exporter of the raw materials for the drug production. Apart from this, it is cost-effective drug in India costing nearly lesser than rupees three per tablet. Moreover, the drug has been advocated in countries like India as a measure to prevent the coronavirus in people who have been in contact with COVID positive persons and those falling in high risk zone. All these aforementioned aspects are likely to favorably leverage the growth of the Hydroxychloroquine market over the forecast period.

Some of the key players profiled in the Hydroxychloroquine Market include Hikma Pharmaceuticals PLC, Cadila Healthcare Ltd, Ipca Laboratories Ltd, Novartis AG , Mylan N.V, Sanofi S.A, Taj Pharmaceuticals Ltd , Shanghai Pharmaceuticals Holding Co., Ltd, Torrent Pharmaceuticals Ltd, Teva Pharmaceutical Industries Ltd , Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Ltd, and Zydus Cadila.

Types Covered:

  • Tablets
  • Injection

Route of Administrations Covered:

  • Oral
  • Intravenous

Grades Covered:

  • United States Pharmacopeial Convention (USP) Standards Grade
  • Pharmaceutical Standards Grade
  • European Pharmacopoeia (EP) Standards Grade

Strengths Covered:

  • 100 mg
  • 200 mg
  • 250 mg
  • 400 mg
  • 500 mg
  • 800 mg

Distribution Channels Covered:

  • Hospital Pharmacy
  • Online Pharmacy
  • Speciality Drug Stores
  • Retail Pharmacy
  • Homeocare

Applications Covered:

  • Malaria
  • Rheumatoid arthritis
  • Lupus Erythematosus
  • Skin Lesions
  • COVID-19

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2017, 2018, 2019, 2023 and 2027
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Hydroxychloroquine Market, By Type

  • 5.1 Introduction
  • 5.2 Tablets
  • 5.3 Injection

6 Global Hydroxychloroquine Market, By Route of Administration

  • 6.1 Introduction
  • 6.2 Oral
  • 6.3 Intravenous

7 Global Hydroxychloroquine Market, By Grade

  • 7.1 Introduction
  • 7.2 United States Pharmacopeial Convention (USP) Standards Grade
  • 7.3 Pharmaceutical Standards Grade
  • 7.4 European Pharmacopoeia (EP) Standards Grade

8 Global Hydroxychloroquine Market, By Strength

  • 8.1 Introduction
  • 8.2 100 mg
  • 8.3 200 mg
  • 8.4 250 mg
  • 8.5 400 mg
  • 8.6 500 mg
  • 8.7 800 mg

9 Global Hydroxychloroquine Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Hospital Pharmacy
  • 9.3 Online Pharmacy
  • 9.4 Speciality Drug Stores
  • 9.5 Retail Pharmacy
  • 9.6 Homeocare

10 Global Hydroxychloroquine Market, By Application

  • 10.1 Introduction
  • 10.2 Malaria
  • 10.3 Rheumatoid arthritis
  • 10.4 Lupus Erythematosus
    • 10.4.1 Systemic Lupus Erythematosus
    • 10.4.2 Chronic Discoid Lupus Erythematosus
  • 10.5 Skin Lesions
  • 10.6 COVID-19

11 Global Hydroxychloroquine Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Hikma Pharmaceuticals PLC
  • 13.2 Cadila Healthcare Ltd
  • 13.3 Ipca Laboratories Ltd
  • 13.4 Novartis AG
  • 13.5 Mylan N.V
  • 13.6 Sanofi S.A
  • 13.7 Taj Pharmaceuticals Ltd
  • 13.8 Shanghai Pharmaceuticals Holding Co., Ltd
  • 13.9 Torrent Pharmaceuticals Ltd
  • 13.10 Teva Pharmaceutical Industries Ltd
  • 13.11 Dr. Reddy's Laboratories Ltd
  • 13.12 Sun Pharmaceutical Industries Ltd
  • 13.13 Zydus Cadila
Back to Top
전화 문의
F A Q